Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
An editorial review of Found's GLP-1 program. The real total cost (not the $149 headline), all 10 medications, and how it compares to Shed, Eden, and Hers.
Found is one of the most-discussed GLP-1 telehealth programs in the U.S., and the pricing story has shifted since we first reviewed it. Found's compounded GLP-1 Program (semaglutide, tirzepatide, or liraglutide) is now a single bundled price with the medication included: $169/month on a 12-month prepaid plan, or $289/month month to month, no separate membership required. The old split-billing model still applies to Found's brand-name catalog: Foundayo, Wegovy, Zepbound, Mounjaro, and Ozempic each carry a medication price plus a separate $129/month CORE membership. The program itself is legitimate and well-built: 10 medications including the FDA-approved Foundayo oral pill, a free insurance check, and a real care team with clinicians and coaches. The honest verdict is that Found is a strong fit for people who want a full compounded program, may have insurance coverage, or want brand-name access with coaching, and a poor fit for people who want the single cheapest number with no bundled extras.
Answer 10 questions and get a personalized recommendation.
Take the free quiz →Found is a full telehealth weight-management program built around GLP-1 medications, not a prescription mill. The clinical model wraps four layers around the prescription: a licensed clinician who reviews your intake and manages your care, a health coach who handles behavioral and adherence support, a behavior-change app for tracking and habits, and an AI lifestyle concierge for nutrition and lifestyle questions between visits.
The medication catalog is the broadest in the GLP-1 telehealth space. Found offers compounded semaglutide, compounded tirzepatide, and compounded liraglutide as injectables (none of which are FDA-approved as finished products). On the FDA-approved side, Found prescribes Foundayo (orforglipron, Eli Lilly's oral GLP-1 pill), the Wegovy pill, the Wegovy injectable pen, and the Zepbound KwikPen. Off-label, Found will prescribe Ozempic and Mounjaro at essentially retail pricing.
Two things to know before you read the pricing section. Found requires lab work to confirm GLP-1 eligibility, and lab work is not included in any of Found's monthly charges. Patients typically pay $50–$150 per panel out of pocket or through insurance. And state availability for compounded medications shifts as compounding regulations evolve, so confirm at intake which formulations are available where you live.
Found
From $169/mo all-in (12-month compounded plan, medication included)
Full program with insurance check, clinicians, coaches, and the broadest medication catalog in GLP-1 telehealth.
Most Found reviews repeat an old marketing headline and stop there. Here is what actually happens at checkout, re-verified in October 2026.
Found now runs two different pricing structures depending on what you're buying.
Compounded GLP-1s are bundled, no separate membership. The compounded GLP-1 Program (semaglutide, tirzepatide, or liraglutide, all injectable) is one price that already includes the medication, the clinician, the coaching, and the app:
| Compounded plan | Monthly rate |
|---|---|
| 12-month prepaid plan | $169/mo |
| Month-to-month | $289/mo |
| With qualifying insurance, 12-month | $99/mo |
| With qualifying insurance, monthly | $199/mo |
That's a real change from the split-billing model this article originally reviewed, which charged the medication and the CORE membership as two separate line items. Compounded medications are not FDA-approved as finished products.
Brand-name medications still split the medication price and a CORE membership. CORE now runs $129/month month to month, roughly $116/month on a quarterly plan, and roughly $99/month on a 6-month prepay; Found no longer publishes a 12-month CORE tier.
| Medication | Medication price | CORE membership | Total (month-to-month) |
|---|---|---|---|
| Foundayo (orforglipron, 0.8mg starter) | From $149/mo | $129/mo | ~$278/mo |
| Wegovy pill or injectable pen | From $650/mo (unconfirmed per dose) | $129/mo | ~$779/mo |
| Zepbound KwikPen | From $650/mo (unconfirmed per dose) | $129/mo | ~$779/mo |
| Mounjaro (off-label) | ~$1,100/mo | $129/mo | ~$1,229/mo |
| Ozempic (off-label) | ~$1,100/mo | $129/mo | ~$1,229/mo |
A few notes on this table. Foundayo escalates by dose, from $149 at the 0.8mg starter toward $299 at maintenance doses. Found's own pricing page no longer shows a per-dose breakdown for Wegovy or Zepbound, just a "from $650/month plus" figure with no ladder, so we could not confirm the exact per-dose price at checkout; treat that row as unconfirmed and expect Found to be materially more expensive than going directly through NovoCare (Wegovy from $149/month) or LillyDirect (Zepbound from $299/month). The off-label Mounjaro and Ozempic prices are essentially retail because there is no manufacturer cash-pay program for either at weight-loss doses.
Lab work is on top of all of this and runs $50–$150 per panel, typically once at intake and periodically thereafter.
The PLUS insurance pathway for brand-name medication is a separate structure entirely. If you have insurance, Found's free insurance check tells you whether your plan covers a GLP-1. If it does, you enroll in PLUS at $39/month and pay your copay through the pharmacy, with a $50/month GLP-1 Bridge program available for Medicare patients aged 65 to 75 with Part D. Found handles the prior authorization coordination, which can be the bottleneck that prevents patients from getting brand-name medication covered. Total cost on this pathway depends on your copay structure, but $39/mo plus a typical $25–$100 copay is materially cheaper than self-paying for any FDA-approved GLP-1.
Most GLP-1 telehealth providers offer two or three medications: usually compounded semaglutide, compounded tirzepatide, and one or two brand-name options. Found offers ten. That catalog breadth is a real differentiator.
The compounded options cover semaglutide, tirzepatide, and liraglutide as injectables. Compounded liraglutide is unusual: most providers stick to semaglutide and tirzepatide, and liraglutide's once-daily injection schedule makes it less commercially appealing. Found carrying it suggests the clinical model takes patient-specific dosing seriously, since liraglutide has a useful role for patients who don't tolerate the longer-acting GLP-1s.
The FDA-approved catalog is wide. Foundayo, Eli Lilly's once-daily oral pill, is one of the newest GLP-1 options on the market and Found is one of the few telehealth providers prescribing it. The Wegovy pill and Wegovy injectable pen cover both delivery preferences for Novo Nordisk's semaglutide. The Zepbound KwikPen rounds out the tirzepatide brand side.
The off-label Mounjaro and Ozempic rows are honestly more legal-coverage than value. Both run at retail pricing through Found because neither manufacturer offers a cash-pay program at weight-loss doses. If you specifically want Mounjaro or Ozempic at a real discount, no telehealth provider can deliver it. The realistic alternative is Wegovy pen for semaglutide or Zepbound for tirzepatide.
For a closer look at how the oral options compare, see our Foundayo vs Wegovy pill breakdown.
Found is built around the idea that GLP-1 medication is more effective when paired with structured behavioral support. The care team includes licensed clinicians who manage prescriptions, dose escalation, and side-effect monitoring, plus health coaches who handle the behavioral side. The Found app provides habit tracking, meal logging, and content modules. The AI lifestyle concierge fields the in-between questions that don't quite warrant a clinician message.
For patients new to GLP-1s, this structure delivers genuine value. Side effects like nausea, constipation, and reflux are common in the early weeks, and having a clinician proactively follow up on them can be the difference between staying on the medication and quitting. The coaching layer also matters for the part of GLP-1 outcomes that depends on diet quality and protein intake, especially for preserving lean mass.
For returning GLP-1 users who know what they're doing, the same structure can feel like overhead. If you're on a brand-name medication and don't plan to use the app or engage with coaching, you'll pay $99–$129/month in CORE membership for services you don't use. On the compounded plan, that overhead is now baked into the single bundled price rather than a separate charge.
This is the part of Found that doesn't have a clean equivalent elsewhere in our roster.
Found's free insurance check happens before you pay anything. You submit your insurance information at intake, Found contacts the insurer, and you get back a written report of which GLP-1s your plan covers, what the prior-authorization requirements look like, and what your expected out-of-pocket would be. Most other providers leave this work to the patient, which in practice means most patients never figure out whether they're covered.
If you're covered, the PLUS pathway is $39/month for Found's coordination work, and the actual medication ships through your insurance and pharmacy at a copay. Found also handles the prior authorization paperwork, which routinely takes weeks if you try to do it yourself. For patients whose plans cover Wegovy or Zepbound but who have been stuck in PA limbo, this is the most direct path to coverage in the GLP-1 telehealth market.
For a broader look at coverage questions, see our GLP-1 insurance coverage guide.
Found's compounded semaglutide, tirzepatide, and liraglutide are not FDA-approved as finished products (FDA, 2024). They use the same active ingredients as Wegovy, Zepbound, and Saxenda, but the finished compounded formulations have not gone through FDA approval.
The regulatory landscape shifted significantly in late 2024 and 2025. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, with enforcement discretion ending in spring 2025 (FDA statement on compounders as GLP-1 supply stabilizes). Novo Nordisk and Eli Lilly have pursued legal action against compounding pharmacies and telehealth platforms over the past 18 months. Compounded access remains legal under specific circumstances, including documented clinical need based on dose or formulation, but the regulatory environment is less stable than it was a year ago.
None of this is unique to Found, but it is part of the calculus for choosing a compounded option through any telehealth provider.
Pros
Cons
Found fits if you:
Found does not fit if you:
Three providers cover overlapping ground in different ways.
Shed is the closest peer on catalog breadth. Shed offers compounded semaglutide and tirzepatide in injectable, microdose, sublingual lozenge, and oral-drop formats, plus brand Wegovy pill, Wegovy injectable, Zepbound, and Foundayo. Shed's compounded semaglutide is $159/month on its 12-month plan versus Found's bundled $169/month, and Shed's brand-name pricing (a separate $125/mo Shed Membership plus medication) publishes a clear per-dose ladder, landing the Wegovy pill total at $274/mo all-in versus an unconfirmed "from $650/mo plus $129/mo" at Found. If you want the broadest format options or a transparent brand-name Wegovy price, Shed is the comparison to make.
Eden is the simpler and now clearly cheaper compounded option. Eden dropped its separate membership for compounded GLP-1s: compounded semaglutide is $99/month and compounded tirzepatide is $129/month, all-inclusive at every dose and month to month, and Eden advertises a lifetime price guarantee on those rates. That is $70/month less than Found's 12-month plan for semaglutide and $190/month less than Found's month-to-month rate, without a prepay commitment. Eden's brand-name Wegovy and Zepbound are a different story: they are priced at Eden's own cash rate ($1,695 and $1,399/month) plus a $99/month membership, far above NovoCare or LillyDirect. The trade-off with Eden: no structured behavioral coaching, no insurance-check service, and no routine lab work before prescribing, which makes for a lighter intake than Found's.
Hers is the brand-name-only alternative through a Novo Nordisk partnership. Hers prescribes Wegovy pill, Wegovy pen, Foundayo, Zepbound, Ozempic, and Mounjaro on a $149/month membership ($39 for the first month). Same structure as Hims but explicitly women-focused. For patients who don't want compounded and want a single membership covering the brand catalog, Hers is the cleaner path.
Shed
From $159/mo compounded (12-month plan), $274/mo Wegovy pill all-in
Closest catalog peer to Found, with broader format options and transparent brand-name Wegovy pricing.
For a full price-by-dose comparison across providers, see the cheapest semaglutide online breakdown or the live GLP-1 pricing tool.
Found is a legitimate, well-built program with the broadest medication catalog in GLP-1 telehealth and the strongest insurance support we've reviewed. The compounded GLP-1 Program is now a genuinely bundled $169/month (12-month plan) or $289/month (month to month), medication included, a real change from the split-billing model this review originally covered. Brand-name medication still splits the price and the $129/month CORE membership, and Found's own pricing page no longer shows what that actually totals per dose, so confirm the brand-name number at intake before assuming it's competitive. If you have insurance, the free insurance check and PLUS pathway can drop the all-in cost dramatically and is genuinely worth running before paying anyone for self-pay GLP-1.
If you want a flat-rate, minimal-support compounded program with no bundled coaching, Eden is the cheapest we track at $99/month for semaglutide or $129/month for tirzepatide, all-inclusive with no membership. If you want the broadest format options and a transparent brand-name Wegovy price, Shed is the closer fit. If you want brand-name-only with no compounded option, Hers covers that lane cleanly.
As with any GLP-1, talk to a licensed healthcare provider before starting or switching medications. Side-effect profiles, contraindications, and dose escalation all warrant a real clinical conversation, not just a checkout flow.
Found
From $169/mo all-in (12-month compounded plan, medication included)
Run the free insurance check before committing: it's the fastest way to know if you're covered.